Lyell Immunopharma CEO Vesting Triggers 40,000-Share Issuance; 7,257 Sold
Rhea-AI Filing Summary
Seely Lynn, who serves as President and CEO and a director of Lyell Immunopharma, reported the issuance and a subsequent sale of company common stock. Per performance-based restricted stock units granted on February 9, 2024, 40,000 shares were recorded as issued on 08/20/2025, with 20,000 shares issued immediately upon certification of performance and the remaining 20,000 shares scheduled for issuance on 08/20/2026 subject to continued service. The next day, 7,257 shares were sold automatically to cover tax withholding at a weighted average price of $10.544 (sales ranged $10.49 to $10.64). After these transactions the reporting person beneficially owned 67,571 shares.
Positive
- Performance criteria met leading to issuance of equity reflects achievement of goals certified by the compensation committee
- Transparent disclosure of both the issuance, the tax-withholding sale, and the sale price range ( $10.49 to $10.64 )
Negative
- Additional shares to be issued (20,000 on 08/20/2026) create potential future dilution for existing shareholders
- Automatic sale of 7,257 shares reduced the reporting person’s immediate holdings and was executed within a narrow price range
Insights
TL;DR: Routine insider vesting and tax-withholding sale; limited immediate market impact.
The filing documents the vesting of performance-based restricted stock units and an automatic sale to satisfy tax withholding. The issuance of 40,000 shares increases the insider's holdings in line with prior compensation awards, while the 7,257-share disposition was a non-discretionary sale to cover taxes at a weighted average of $10.544. These actions are standard for equity compensation programs and do not, on their face, signal a change in corporate strategy or material disposition of holdings beyond withholding.
TL;DR: Compensation committee certified performance; disclosure aligns with Section 16 reporting requirements.
The form shows the compensation committee certified achievement of performance criteria triggering partial issuance of performance RSUs, with the remaining tranche conditioned on future service. The clear explanation of the vesting schedule and tax-withholding sale reflects appropriate disclosure practices. The scheduled future issuance of 20,000 shares remains subject to service through the specified date, which is disclosed in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,257 | $10.544 | $77K |
| Grant/Award | Common Stock | 40,000 | $0.00 | -- |
Footnotes (1)
- Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 20,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
